Skip to content
2000
Volume 32, Issue 7
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Breast cancer remains one of the most challenging malignancies worldwide due to its heterogeneity, which affects tumor behavior, progression, and treatment response. The complexity of breast cancer necessitates innovative therapeutic strategies to improve treatment outcomes. This review explores the potential of vesicular nanocarriers, including liposomes, niosomes, ethosomes, polymerosomes, phytosomes, and transferosomes, in enhancing breast cancer treatment efficacy through targeted drug delivery. A detailed analysis of recent progress in the functionalization and application of vesicular nanocarriers is discussed, highlighting their contribution to enhancing pharmacokinetics, drug solubility, and targeted delivery. Both passive and active targeting strategies were assessed for their ability to enhance tumor-specific drug accumulation. Vesicular nanocarriers offer significant advantages, including reduced systemic toxicity, improved drug bioavailability, and precise delivery to cancer cells. Passive targeting utilizes the enhanced permeation and retention effect for tumor accumulation, while active targeting employs surface modifications with antibodies, aptamers, or peptides to enhance specificity. The integration of vesicular nanocarriers in breast cancer therapy presents a promising strategy for more effective and personalized treatment approaches. Their ability to optimize drug delivery and minimize off-target effects highlights their potential to revolutionize breast cancer treatment.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128385024250625212516
2025-07-14
2026-03-06

  • From This Site

    /content/journals/cpd/10.2174/0113816128385024250625212516
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KothariC. DiorioC. DurocherF. The importance of breast adipose tissue in breast cancer.Int. J. Mol. Sci.20202116576010.3390/ijms21165760 32796696
     [Google Scholar]
  2. HoughtonS.C. HankinsonS.E. Cancer progress and priorities: Breast cancer.Cancer Epidemiol. Biomarkers Prev.202130582284410.1158/1055‑9965.EPI‑20‑1193 33947744
     [Google Scholar]
  3. WilkinsonL. GathaniT. Understanding breast cancer as a global health concern.Br. J. Radiol.20229511302021103310.1259/bjr.20211033 34905391
     [Google Scholar]
  4. Breast cancer statistics | facts & figures | NBCC.2022Available from: https://www.stopbreastcancer.org/information-center/facts-figures/
  5. Breast cancer awareness month, knowledge and news on women’s health (KNOWH) blog from FDA Office of women’s health.2024Available from: https://www.fda.gov/consumers/knowledgeand-news-women-owh-blog/breast-cancer-awareness-month#:~:text=October%20is%20Breast%20Cancer%20Awareness%20month!&text=Approximately%20one%20in%20eight%20women,women%20die%20from%20breast%20cancer
  6. SurakasulaA. NagarjunapuG. RaghavaiahK.V. A comparative study of pre- and post-menopausal breast cancer: Risk factors, presentation, characteristics and management.J. Res. Pharm. Pract.201431121810.4103/2279‑042X.132704 24991630
     [Google Scholar]
  7. DallG.V. BrittK.L. Estrogen effects on the mammary gland in early and late life and breast cancer risk.Front. Oncol.2017711010.3389/fonc.2017.00110 28603694
     [Google Scholar]
  8. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease.Lancet200135892911389139910.1016/S0140‑6736(01)06524‑2 11705483
     [Google Scholar]
  9. SmolarzB. NowakA.Z. RomanowiczH. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature).Cancers20221410256910.3390/cancers14102569 35626173
     [Google Scholar]
  10. SheaE.K.H. KohV.C.Y. TanP.H. Invasive breast cancer: Current perspectives and emerging views.Pathol. Int.202070524225210.1111/pin.12910 32039524
     [Google Scholar]
  11. ChenM. WuJ. LiuD. Combined estrogen receptor and progesterone receptor level can predict survival outcome in human epidermal growth factor receptor 2-positive early breast cancer.Clin. Breast Cancer2022222e147e15610.1016/j.clbc.2021.05.012 34244052
     [Google Scholar]
  12. FeiF. SiegalG.P. WeiS. Characterization of estrogen receptor-low-positive breast cancer.Breast Cancer Res. Treat.2021188122523510.1007/s10549‑021‑06148‑0 33694051
     [Google Scholar]
  13. PandeyP. Kumar AryaD. Kumar RamarM. ChidambaramK. RajinikanthP.S. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy.Drug Discov. Today20222792526254010.1016/j.drudis.2022.06.007 35753642
     [Google Scholar]
  14. SønderstrupI.M.H. JensenM.B.R. EjlertsenB. Subtypes in BRCA-mutated breast cancer.Hum. Pathol.20198419220110.1016/j.humpath.2018.10.005 30342055
     [Google Scholar]
  15. Guzmán-ArochoY.D. RosenbergS.M. GarberJ.E. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.Br. J. Cancer2022126230230910.1038/s41416‑021‑01597‑2 34703009
     [Google Scholar]
  16. LoiblS. GianniL. HER2-positive breast cancer.Lancet2017389100872415242910.1016/S0140‑6736(16)32417‑5 27939064
     [Google Scholar]
  17. RakhaE.A. Reis-FilhoJ.S. EllisI.O. Basal-like breast cancer: A critical review.J. Clin. Oncol.200826152568258110.1200/JCO.2007.13.1748 18487574
     [Google Scholar]
  18. Fujiwara-TaniR. MoriS. OgataR. Claudin-4: A new molecular target for epithelial cancer therapy.Int. J. Mol. Sci.2023246549410.3390/ijms24065494 36982569
     [Google Scholar]
  19. TewabeA. AbateA. TamrieM. SeyfuA. Abdela SirajE. Targeted drug delivery - from magic bullet to nanomedicine: Principles, challenges, and future perspectives.J. Multidiscip. Healthc.2021141711172410.2147/JMDH.S313968 34267523
     [Google Scholar]
  20. KundeS.S. WairkarS. Targeted delivery of albumin nanoparticles for breast cancer: A review.Colloids Surf. B Biointerfaces202221311242210.1016/j.colsurfb.2022.112422 35231688
     [Google Scholar]
  21. DinF. AmanW. UllahI. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.Int. J. Nanomedicine2017127291730910.2147/IJN.S146315 29042776
     [Google Scholar]
  22. KyriakoudiA. SpanidiE. MourtzinosI. GardikisK. Innovative delivery systems loaded with plant bioactive ingredients: formulation approaches and applications.Plants2021106123810.3390/plants10061238 34207139
     [Google Scholar]
  23. ChavdaV.P. NallaL.V. BalarP. Advanced phytochemical-based nanocarrier systems for the treatment of breast cancer.Cancers2023154102310.3390/cancers15041023 36831369
     [Google Scholar]
  24. ChengH. LiaoJ. MaY. SarwarM.T. YangH. Advances in targeted therapy for tumor with nanocarriers: A review.Mater. Today Bio20253110158310.1016/j.mtbio.2025.101583 40061211
     [Google Scholar]
  25. CostaB. AmorimI. GärtnerF. ValeN. Understanding breast cancer: From conventional therapies to repurposed drugs.Eur. J. Pharm. Sci.202015110540110.1016/j.ejps.2020.105401 32504806
     [Google Scholar]
  26. BurguinA. DiorioC. DurocherF. Breast cancer treatments: Updates and new challenges.J. Pers. Med.202111880810.3390/jpm11080808 34442452
     [Google Scholar]
  27. DarbyS. McGaleP. CorreaC. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials.Lancet201137898041707171610.1016/S0140‑6736(11)61629‑2 22019144
     [Google Scholar]
  28. BalajiK. SubramanianB. YadavP. Anu RadhaC. RamasubramanianV. Radiation therapy for breast cancer: Literature review.Med. Dosim.201641325325710.1016/j.meddos.2016.06.005 27545009
     [Google Scholar]
  29. MayoC.S. UrieM.M. FitzgeraldT.J. Hybrid IMRT plans-concurrently treating conventional and IMRT beams for improved breast irradiation and reduced planning time.Int. J. Radiat. Oncol. Biol. Phys.200561392293210.1016/j.ijrobp.2004.10.033 15708276
     [Google Scholar]
  30. HortobagyiG.N. Progress in systemic chemotherapy of primary breast cancer: An overview.J. Natl. Cancer Inst. Monogr.2001200130727910.1093/oxfordjournals.jncimonographs.a003465 11773296
     [Google Scholar]
  31. EzikeT.C. OkpalaU.S. OnojaU.L. Advances in drug delivery systems, challenges and future directions.Heliyon202396e1748810.1016/j.heliyon.2023.e17488 37416680
     [Google Scholar]
  32. HuangL. HuangX.H. YangX. Novel nano-drug delivery system for natural products and their application.Pharmacol. Res.202420110710010.1016/j.phrs.2024.107100 38341055
     [Google Scholar]
  33. AmjadM.T. ChidharlaA. KasiA. Cancer Chemotherapy.In: StatPearls.Treasure Island (FL)StatPearls Publishing2025 33232037
     [Google Scholar]
  34. EmranT.B. ShahriarA. MahmudA.R. Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches.Front. Oncol.20221289165210.3389/fonc.2022.891652 35814435
     [Google Scholar]
  35. BassiouniY. FaddahL. Nanocarrier-based drugs: The future promise for treatment of breast cancer.J. Appl. Pharm. Sci.20122522523210.7324/JAPS.2012.2530
     [Google Scholar]
  36. WidakowichC. de AzambujaE. GilT. Molecular targeted therapies in breast cancer: Where are we now?Int. J. Biochem. Cell Biol.2007397-81375138710.1016/j.biocel.2007.04.015 17543572
     [Google Scholar]
  37. DhankharR. VyasS.P. JainA.K. AroraS. RathG. GoyalA.K. Advances in novel drug delivery strategies for breast cancer therapy.Artif. Cells Blood Substit. Immobil. Biotechnol.201038523024910.3109/10731199.2010.494578 20677900
     [Google Scholar]
  38. KeX. ShenL. Molecular targeted therapy of cancer: The progress and future prospect.Frontiers in Laboratory Medicine201712697510.1016/j.flm.2017.06.001
     [Google Scholar]
  39. StrebhardtK. UllrichA. Paul Ehrlich’s magic bullet concept: 100 years of progress.Nat. Rev. Cancer20088647348010.1038/nrc2394 18469827
     [Google Scholar]
  40. WilkesG.M. Targeted therapy: Attacking cancer with molecular and immunological targeted agents.Asia Pac. J. Oncol. Nurs.20185213715510.4103/apjon.apjon_79_17 29607374
     [Google Scholar]
  41. WangX. ZhangH. ChenX. Drug resistance and combating drug resistance in cancer.Cancer Drug Resist.20192214116010.20517/cdr.2019.10 34322663
     [Google Scholar]
  42. SherrC.J. BartekJ. Cell cycle–targeted cancer therapies.Annu. Rev. Cancer Biol.201711415710.1146/annurev‑cancerbio‑040716‑075628
     [Google Scholar]
  43. HanahanD WeinbergRA Hallmarks of cancer: The next generation.cell201114456467410.1016/j.cell.2011.02.01321376230
     [Google Scholar]
  44. MukherjeeD. RaikwarS. Recent update on nanocarrier(s) as the targeted therapy for breast cancer.AAPS PharmSciTech202425615310.1208/s12249‑024‑02867‑x 38961013
     [Google Scholar]
  45. WuJ. The enhanced permeability and retention (EPR) effect: The significance of the concept and methods to enhance its application.J. Pers. Med.202111877110.3390/jpm11080771 34442415
     [Google Scholar]
  46. GolombekS.K. MayJ.N. TheekB. Tumor targeting via EPR: Strategies to enhance patient responses.Adv. Drug Deliv. Rev.2018130173810.1016/j.addr.2018.07.007 30009886
     [Google Scholar]
  47. PetersenA.L. HansenA.E. GabizonA. AndresenT.L. Liposome imaging agents in personalized medicine.Adv. Drug Deliv. Rev.201264131417143510.1016/j.addr.2012.09.003 22982406
     [Google Scholar]
  48. BertrandN. WuJ. XuX. KamalyN. FarokhzadO.C. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology.Adv. Drug Deliv. Rev.20146622510.1016/j.addr.2013.11.009 24270007
     [Google Scholar]
  49. DeshpandeP.P. BiswasS. TorchilinV.P. Current trends in the use of liposomes for tumor targeting.Nanomedicine2013891509152810.2217/nnm.13.118 23914966
     [Google Scholar]
  50. GlasgowM.D.K. ChouguleM.B. Recent developments in active tumor targeted multifunctional nanoparticles for combination chemotherapy in cancer treatment and imaging.J. Biomed. Nanotechnol.201511111859189810.1166/jbn.2015.2145 26554150
     [Google Scholar]
  51. Di LorenzoG. RicciG. SeveriniG.M. RomanoF. BiffiS. Imaging and therapy of ovarian cancer: Clinical application of nanoparticles and future perspectives.Theranostics20188164279429410.7150/thno.26345 30214620
     [Google Scholar]
  52. BiffiS. VoltanR. RampazzoE. ProdiL. ZauliG. SecchieroP. Applications of nanoparticles in cancer medicine and beyond: Optical and multimodal in vivo imaging, tissue targeting and drug delivery.Expert Opin. Drug Deliv.201512121837184910.1517/17425247.2015.1071791 26289673
     [Google Scholar]
  53. LiR. ZhengK. YuanC. ChenZ. HuangM. Be active or not: The relative contribution of active and passive tumor targeting of nanomaterials.Nanotheranostics20171434635710.7150/ntno.19380 29071198
     [Google Scholar]
  54. BiffiS. VoltanR. BortotB. ZauliG. SecchieroP. Actively targeted nanocarriers for drug delivery to cancer cells.Expert Opin. Drug Deliv.201916548149610.1080/17425247.2019.1604679 30955393
     [Google Scholar]
  55. JainS. JainV. MahajanS. Lipid based vesicular drug delivery systems.Advances in Pharmaceutics201420141574673
     [Google Scholar]
  56. SoltaniF. ParhizH. MokhtarzadehA. RamezaniM. Synthetic and biological vesicular nano-carriers designed for gene delivery.Curr. Pharm. Des.201521426214623510.2174/1381612821666151027153410 26503143
     [Google Scholar]
  57. KapoorB. GuptaR. GulatiM. SinghS.K. KhursheedR. GuptaM. The why, where, who, how, and what of the vesicular delivery systems.Adv. Colloid Interface Sci.201927110198510.1016/j.cis.2019.07.006 31351415
     [Google Scholar]
  58. PandeS. Liposomes for drug delivery: Review of vesicular composition, factors affecting drug release and drug loading in liposomes.Artif. Cells Nanomed. Biotechnol.202351142844010.1080/21691401.2023.2247036 37594208
     [Google Scholar]
  59. GuimarãesD. Cavaco-PauloA. NogueiraE. Design of liposomes as drug delivery system for therapeutic applications.Int. J. Pharm.202160112057110.1016/j.ijpharm.2021.120571 33812967
     [Google Scholar]
  60. WangJ. GongJ. WeiZ. Strategies for liposome drug delivery systems to improve tumor treatment efficacy.AAPS PharmSciTech20222312710.1208/s12249‑021‑02179‑4 34907483
     [Google Scholar]
  61. RolleF. BincolettoV. GazzanoE. Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells.Int. J. Pharm.202058011919110.1016/j.ijpharm.2020.119191 32142738
     [Google Scholar]
  62. LiuD. ZhangQ. WangJ. GuanS. CaiD. LiuJ. Inhibition of growth and metastasis of breast cancer by targeted delivery of 17-hydroxy-jolkinolide B via hyaluronic acid-coated liposomes.Carbohydr. Polym.202125711757210.1016/j.carbpol.2020.117572 33541631
     [Google Scholar]
  63. BhardwajP. TripathiP. GuptaR. PandeyS. Niosomes: A review on niosomal research in the last decade.J. Drug Deliv. Sci. Technol.20205610158110.1016/j.jddst.2020.101581
     [Google Scholar]
  64. MarianecciC. Di MarzioL. RinaldiF. Niosomes from 80s to present: The state of the art.Adv. Colloid Interface Sci.201420518720610.1016/j.cis.2013.11.018 24369107
     [Google Scholar]
  65. MoammeriA. ChegeniM.M. SahrayiH. Current advances in niosomes applications for drug delivery and cancer treatment.Mater. Today Bio20232310083710.1016/j.mtbio.2023.100837 37953758
     [Google Scholar]
  66. MehraryaM. GharehchelouB. Haghighi PoodehS. Niosomal formulation for antibacterial applications.J. Drug Target.202230547649310.1080/1061186X.2022.2032094 35060818
     [Google Scholar]
  67. HaseliS. PourmadadiM. SamadiA. A novel pH ‐responsive nanoniosomal emulsion for sustained release of curcumin from a chitosan‐based nanocarrier: Emphasis on the concurrent improvement of loading, sustained release, and apoptosis induction.Biotechnol. Prog.2022385e328010.1002/btpr.3280 35678755
     [Google Scholar]
  68. ChenS. HanningS. FalconerJ. LockeM. WenJ. Recent advances in non-ionic surfactant vesicles (niosomes): Fabrication, characterization, pharmaceutical and cosmetic applications.Eur. J. Pharm. Biopharm.2019144183910.1016/j.ejpb.2019.08.015 31446046
     [Google Scholar]
  69. SaharkhizS. NasriN. NaderiN. DiniG. GhalehshahiS.S. FiroozbakhtF. Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells.Int. J. Pharm. X2024710023710.1016/j.ijpx.2024.100237 38516198
     [Google Scholar]
  70. TouitouE. DayanN. BergelsonL. GodinB. EliazM. Ethosomes — novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties.J. Control. Release200065340341810.1016/S0168‑3659(99)00222‑9 10699298
     [Google Scholar]
  71. AbdulbaqiI.M. DarwisY. KhanN.A. AssiR.A. KhanA.A. Ethosomal nanocarriers: The impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials.Int. J. Nanomedicine2016112279230410.2147/IJN.S105016 27307730
     [Google Scholar]
  72. Paiva-SantosA.C. SilvaA.L. GuerraC. Ethosomes as nanocarriers for the development of skin delivery formulations.Pharm. Res.202138694797010.1007/s11095‑021‑03053‑5 34036520
     [Google Scholar]
  73. ChauhanN. VasavaP. KhanS.L. Ethosomes: A novel drug carrier.Ann. Med. Surg.20228210459510.1016/j.amsu.2022.104595 36124209
     [Google Scholar]
  74. PatelD. BhargavaP. Ethosomes-A phyto drug delivery system.Adv Res Bio Pharm2012218
     [Google Scholar]
  75. RomeroE. MorillaM. Highly deformable and highly fluid vesicles as potential drug delivery systems: Theoretical and practical considerations.Int. J. Nanomedicine201383171318610.2147/IJN.S33048 23986634
     [Google Scholar]
  76. RathoreA. KhambeteH. JainS. Preparation and characterization of repaglinide loaded ethosomal gel for the treatment of NIDDM.Int. J. Pharm. Biol. Arch.201342385390
     [Google Scholar]
  77. KumarN. DubeyA. MishraA. TiwariP. Ethosomes: A novel approach in transdermal drug delivery system.Int J Pharm Life Sci2020115
     [Google Scholar]
  78. NasriS. Ebrahimi-HosseinzadehB. RahaieM. Hatamian-ZarmiA. SahraeianR. Thymoquinone-loaded ethosome with breast cancer potential: Optimization, in vitro and biological assessment.J. Nanostructure Chem.2020101193110.1007/s40097‑019‑00325‑w
     [Google Scholar]
  79. NaikU.S. The synthesis and characterisation of novel ultra-flexible lipidic vesicles using propanol.Masters thesis, University of Central Lancashire2013
     [Google Scholar]
  80. RajanR. JoseS. Biju MukundV.P. VasudevanD. Transferosomes - A vesicular transdermal delivery system for enhanced drug permeation.J. Adv. Pharm. Technol. Res.20112313814310.4103/2231‑4040.85524 22171309
     [Google Scholar]
  81. SachanR. ParasharT. SinghV. SinghG. TyagiS. PatelC. Drug carrier transfersomes: A novel tool for transdermal drug delivery system.IJRDPL201322309316
     [Google Scholar]
  82. OpathaS.A.T. TitapiwatanakunV. ChutoprapatR. Transfersomes: A promising nanoencapsulation technique for transdermal drug delivery.Pharmaceutics202012985510.3390/pharmaceutics12090855 32916782
     [Google Scholar]
  83. ChenM. ShamimM.A. ShahidA. Topical delivery of carvedilol loaded nano-transfersomes for skin cancer chemoprevention.Pharmaceutics20201212115110.3390/pharmaceutics12121151 33260886
     [Google Scholar]
  84. MatharooN. MohdH. Michniak-KohnB. Transferosomes as a transdermal drug delivery system: Dermal kinetics and recent developments.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.2024161e191810.1002/wnan.1918 37527953
     [Google Scholar]
  85. Fernández-GarcíaR. LalatsaA. StattsL. Bolás-FernándezF. BallesterosM.P. SerranoD.R. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale.Int. J. Pharm.202057311881710.1016/j.ijpharm.2019.118817 31678520
     [Google Scholar]
  86. RaiS. PandeyV. RaiG. Transfersomes as versatile and flexible nano-vesicular carriers in skin cancer therapy: The state of the art.Nano Rev. Exp.201781132570810.1080/20022727.2017.1325708 30410704
     [Google Scholar]
  87. PandeyA. MittalA. ChauhanN. AlamS. Role of surfactants as penetration enhancer in transdermal drug delivery system.J. Mol. Pharm. Org. Process Res.2014222710.4172/2329‑9053.1000113
     [Google Scholar]
  88. MishraV. BansalK.K. VermaA. Solid lipid nanoparticles: Emerging colloidal nano drug delivery systems.Pharmaceutics201810419110.3390/pharmaceutics10040191 30340327
     [Google Scholar]
  89. FernandesN.B. VelagacherlaV. SpandanaK.J. Co-delivery of lapatinib and 5-fluorouracil transfersomes using transpapillary iontophoresis for breast cancer therapy.Int. J. Pharm.202465012368610.1016/j.ijpharm.2023.123686 38070658
     [Google Scholar]
  90. DischerB.M. WonY.Y. EgeD.S. Polymersomes: Tough vesicles made from diblock copolymers.Science199928454171143114610.1126/science.284.5417.1143 10325219
     [Google Scholar]
  91. MartinC. AibaniN. CallanJ.F. CallanB. Recent advances in amphiphilic polymers for simultaneous delivery of hydrophobic and hydrophilic drugs.Ther. Deliv.201671153110.4155/tde.15.84 26652620
     [Google Scholar]
  92. ZhuY. CaoS. HuoM. van HestJ.C.M. CheH. Recent advances in permeable polymersomes: Fabrication, responsiveness, and applications.Chem. Sci.202314277411743710.1039/D3SC01707A 37449076
     [Google Scholar]
  93. ArasteF. AliabadiA. AbnousK. TaghdisiS.M. RamezaniM. AlibolandiM. Self-assembled polymeric vesicles: Focus on polymersomes in cancer treatment.J. Control. Release202133050252810.1016/j.jconrel.2020.12.027 33358973
     [Google Scholar]
  94. WuD. AbezgauzL. DaninoD. HoC.C. Alternating polymer vesicles.Soft Matter2008451066107110.1039/b715608a 32907140
     [Google Scholar]
  95. NicolasJ. MuraS. BrambillaD. MackiewiczN. CouvreurP. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery.Chem. Soc. Rev.20134231147123510.1039/C2CS35265F 23238558
     [Google Scholar]
  96. KauscherU. HolmeM.N. BjörnmalmM. StevensM.M. Physical stimuli-responsive vesicles in drug delivery: Beyond liposomes and polymersomes.Adv. Drug Deliv. Rev.201913825927510.1016/j.addr.2018.10.012 30947810
     [Google Scholar]
  97. SueyoshiD. AnrakuY. KomatsuT. UranoY. KataokaK. Enzyme-loaded polyion complex vesicles as in vivo nanoreactors working sustainably under the blood circulation: Characterization and functional evaluation.Biomacromolecules20171841189119610.1021/acs.biomac.6b01870 28233988
     [Google Scholar]
  98. LiY. ThambiT. LeeD.S. Co‐delivery of drugs and genes using polymeric nanoparticles for synergistic cancer therapeutic effects.Adv. Healthc. Mater.201871170088610.1002/adhm.201700886 28941203
     [Google Scholar]
  99. ShahriariM. TaghdisiS.M. AbnousK. RamezaniM. AlibolandiM. Synthesis of hyaluronic acid-based polymersomes for doxorubicin delivery to metastatic breast cancer.Int. J. Pharm.201957211883510.1016/j.ijpharm.2019.118835 31726198
     [Google Scholar]
  100. BaraniM. SangiovanniE. AngaranoM. Phytosomes as innovative delivery systems for phytochemicals: A comprehensive review of literature.Int. J. Nanomedicine2021166983702210.2147/IJN.S318416 34703224
     [Google Scholar]
  101. NagarG. Phytosomes: A novel drug delivery for herbal extracts.Int. J. Pharm. Sci. Res.20199924930
     [Google Scholar]
  102. LuM. QiuQ. LuoX. Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents.Asian J Pharm Sci201914326527410.1016/j.ajps.2018.05.011 32104457
     [Google Scholar]
  103. AlharbiW.S. AlmughemF.A. AlmehmadyA.M. Phytosomes as an emerging nanotechnology platform for the topical delivery of bioactive phytochemicals.Pharmaceutics2021139147510.3390/pharmaceutics13091475 34575551
     [Google Scholar]
  104. KhanzodeM.B. KajaleA.D. ChannawarM.A. GawandeS.R. Review on phytosomes: A novel drug delivery system.GSCBPS202013120321110.30574/gscbps.2020.13.1.0345
     [Google Scholar]
  105. KalitaB. DasM.K. SharmaA.K. Novel phytosome formulations in making herbal extracts more effective.J. Pharm. Technol.201361112951301
     [Google Scholar]
  106. KarpuzM. GunayM.S. OzerA.Y. Liposomes and phytosomes for phytoconstituents.In: Advances and Avenues in the Development of Novel Carriers for Bioactives and Biological Agents.Elsevier202052555310.1016/B978‑0‑12‑819666‑3.00018‑3
     [Google Scholar]
  107. GaikwadS.S. MoradeY.Y. KothuleA.M. KshirsagarS.J. LaddhaU.D. SalunkheK.S. Overview of phytosomes in treating cancer: Advancement, challenges, and future outlook.Heliyon202396e1656110.1016/j.heliyon.2023.e16561 37260890
     [Google Scholar]
  108. TalaatS.M. ElnaggarY.S.R. El-GanainyS.O. GowayedM.A. AllamM. AbdallahO.Y. Self-assembled fisetin-phospholipid complex: Fisetin-integrated phytosomes for effective delivery to breast cancer.Eur. J. Pharm. Biopharm.202318917418810.1016/j.ejpb.2023.06.009 37343893
     [Google Scholar]
  109. GkionisL. CampbellR.A. AojulaH. HarrisL.K. TirellaA. Manufacturing drug co-loaded liposomal formulations targeting breast cancer: Influence of preparative method on liposomes characteristics and in vitro toxicity.Int. J. Pharm.202059011992610.1016/j.ijpharm.2020.119926 33010397
     [Google Scholar]
  110. ChowdhuryN. ChaudhryS. HallN. Targeted delivery of doxorubicin liposomes for her-2+ breast cancer treatment.AAPS PharmSciTech202021620210.1208/s12249‑020‑01743‑8 32696338
     [Google Scholar]
  111. Dabbagh MoghaddamF. AkbarzadehI. MarzbankiaE. FaridM. KhalediL. ReihaniA.H. Delivery of melittin-loaded niosomes for breast cancer treatment: An in vitro and in vivo evaluation of anti-cancer effect.Cancer Nanotechnol.202112114
     [Google Scholar]
  112. KanaaniL. JavadiI. EbrahimifarM. Ebrahimi ShahmabadiH. Akbarzadeh KhiyavA. MehrdibaT. Effects of cisplatin-loaded niosomal nanoparticleson bt-20 human breast carcinoma cells.Asian Pac. J. Cancer Prev.201718236536810.22034/apjcp.2017.18.2.365 28345332
     [Google Scholar]
  113. AlEbadiN.N. Al-LamiM.S. Formulation and in-vitro evaluation of ethosomes using anastrozole as a modeling drug.AJPS20222249010510.32947/ajps.v22i4.971
     [Google Scholar]
  114. ApolinárioA.C. HauschkeL. NunesJ.R. LourençoF.R. LopesL.B. Design of multifunctional ethosomes for topical fenretinide delivery and breast cancer chemoprevention.Colloids Surf. A Physicochem. Eng. Asp.202162312674510.1016/j.colsurfa.2021.126745
     [Google Scholar]
  115. SundralingamU. ChakravarthiS. RadhakrishnanA.K. MuniyandyS. PalanisamyU.D. Efficacy of emu oil transfersomes for local transdermal delivery of 4-OH tamoxifen in the treatment of breast cancer.Pharmaceutics202012980710.3390/pharmaceutics12090807 32854385
     [Google Scholar]
  116. SaxenaA. KoriM.L. Preparation and characterization of pH-responsive transferosomes for transdermal delivery of paclitaxel.Int. J. Adv. Sci. Res.202011012734
     [Google Scholar]
  117. ZavvarT. BabaeiM. AbnousK. Synthesis of multimodal polymersomes for targeted drug delivery and MR/fluorescence imaging in metastatic breast cancer model.Int. J. Pharm.202057811909110.1016/j.ijpharm.2020.119091 32007591
     [Google Scholar]
  118. NosratiH. AdinehvandR. ManjiliH.K. RostamizadehK. DanafarH. Synthesis, characterization, and kinetic release study of methotrexate loaded mPEG-PCL polymersomes for inhibition of MCF-7 breast cancer cell line.Pharm. Dev. Technol.2019241899810.1080/10837450.2018.1425433 29307260
     [Google Scholar]
  119. WanjiruJ. GathirwaJ. SauliE. SwaiH.S. Formulation, optimization, and evaluation of Moringa oleifera leaf polyphenol-loaded phytosome delivery system against breast cancer cell lines.Molecules20222714443010.3390/molecules27144430 35889305
     [Google Scholar]
  120. KomeilI.A. AbdallahO.Y. El-RefaieW.M. Surface modified genistein phytosome for breast cancer treatment: In-vitro appraisal, pharmacokinetics, and in-vivo antitumor efficacy.Eur. J. Pharm. Sci.202217910629710.1016/j.ejps.2022.106297 36156294
     [Google Scholar]
  121. Real-world study of the efficacy and safety of paclitaxel liposome combined with anti-HER-2 monoclonal antibody as first-line salvage treatment of HER-2 positive advanced breast cancer.NCT064815532024
  122. PilotA. A pilot, single-arm, phase II trial of tamoxifen plus pegylated liposomal doxorubicin in patients with metastatic triple negative breast cancer.NCT064340642024
  123. Open-label, single center, single-arm, phase 2 study of neoadjuvant pembrolizumab in combination with carboplatin and paclitaxel in patients with stage 1 cT1b-T1cN0M0 triple negative breast cancer.NCT063188972024
  124. An open-label, randomized phase 3 study of MK-2870 as a single agent and in combination with pembrolizumab versus treatment of physician's choice in participants with HR+/HER2- unresectable locally advanced or metastatic breast cancer.NCT063121762024
  125. JounI. NixdorfS. DengW. Advances in lipid-based nanocarriers for breast cancer metastasis treatment.Front Med Technol2022489305610.3389/fmedt.2022.893056 36062261
     [Google Scholar]
  126. ShiJ. KantoffP.W. WoosterR. FarokhzadO.C. Cancer nanomedicine: Progress, challenges and opportunities.Nat. Rev. Cancer2017171203710.1038/nrc.2016.108 27834398
     [Google Scholar]
  127. KumariN.U. PardhiE. CharyP.S. MehraN.K. Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy.Ther. Deliv.202415427930310.4155/tde‑2023‑0092 38374774
     [Google Scholar]
  128. MugundhanS.L. MohanM. Nanoscale strides: Exploring innovative therapies for breast cancer treatment.RSC Advances20241420140171404010.1039/D4RA02639J 38686289
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128385024250625212516
Loading
Recent Developments in Vesicular Nanocarriers for Targeted Drug Delivery in Breast Cancer
Curr. Pharm. Des. 32, 519 (2026); https://doi.org/10.2174/0113816128385024250625212516
/content/journals/cpd/10.2174/0113816128385024250625212516
/content/journals/cpd/10.2174/0113816128385024250625212516
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): active targeting; Breast cancer; drug targeting; nanocarriers; passive targeting; vesicular nanocarriers

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test